Subjects will be followed annually until study closure.

Assessments are as follows:

1. Clinical (Annual): Demographics, health-related behaviors, co-morbidities, medications, respiratory symptoms, rheumatologic assessment, quality of life
2. Physiologic (3-5 yrs FU): Lung function on Pulmonary Function Test (PFT)
3. Radiologic (3-5 yrs FU): HRCT scan of chest
4. Genetic (3-5 yrs FU): Blood sample collection for RNA
5. Biologic (3-5 yrs FU): Blood sample collection for other blood markers

Subjects will be followed annually until study closure.

Assessments are as follows:

1. Clinical (Annual): Demographics, health-related behaviors, co-morbidities, medications, respiratory symptoms, rheumatologic assessment, quality of life
2. Physiologic (3-5 yrs FU): Lung function on Pulmonary Function Test (PFT)
3. Radiologic (3-5 yrs FU): HRCT scan of chest
4. Genetic (3-5 yrs FU): Blood sample collection for RNA
5. Biologic (3-5 yrs FU): Blood sample collection for other blood markers

Note: Certain follow-up procedures may not occur for every subject and will be determined by the research team.

HRCT scans of the chest will be interpreted by two radiologists and the presence or absence of interstitial lung abnormality will be recorded. When present, abnormalities will be categorized as absent, equivocal, non-fibrotic, or fibrotic, and the extent of any reticular abnormalities will be graded on an 11-point scale (0, 1-10%, 11-20%, etc.). Additionally, the presence or absence of airway disease, centrilobular thickening, mosaic attenuation, and air trapping will be recorded.

Radiologic progression of lung disease will be determined through a comparison of baseline HRCT chest findings to follow-up HRCT chest findings at the 3-5 year follow-up benchmark. Similar to baseline, follow-up HRCT scans of the chest will be interpreted by 2 different radiologists. Quantitative radiologic progression will be defined as ≥ 10% increase in fibrotic changes from baseline to follow-up - additionally, the percent reticular change, percent honeycomb change, and percent traction bronchiectasis on the follow-up scan will be quantified and recorded.

Radiologic findings of progression will be used in correlation with other clinical features to determine the clinical relevance of the change. The clinical features include - change in cough, change in dyspnea (as measured by UCSD shortness of breath questionnaire), change in FVC percent predicted value, the development of established RA-ILD, or respiratory-related death, over the same time period.